Magle Group Secures Registration of SmartPAN® in Singapore, Enabling Launch in Pancreatic Surgery

02/10/2025

Magle Group today announced that its proprietary surgical innovation, SmartPAN®, has been successfully registered in Singapore. This achievement allows the company to initiate the commercial launch of SmartPAN® in one of Asia’s leading healthcare markets.

SmartPAN® is a bioindicator specifically developed to support surgeons in pancreatic surgery. The product provides enhanced visualisation during surgery, helping surgeons to identify and assess potential leakage sites with greater confidence. By offering a clear intraoperative signal, SmartPAN® supports surgical decision-making in one of the most complex and challenging fields of surgery.

Registration in Singapore represents a significant step forward in Magle Group’s global strategy for SmartPAN®, extending access to a technology that reflects the Group’s commitment to patient-centric innovation.

“We are delighted that SmartPAN® has now been successfully registered in Singapore,” said Helena Ossmer Thedius, Chief Marketing & Innovation Officer, Magle Group. “This milestone allows us to bring SmartPAN® to surgeons in a new market, where it can serve as a valuable bioindicator in pancreatic surgery and strengthen surgical confidence in the operating theatre.”

The commercial launch in Singapore will be carried out together with local partners and surgical stakeholders, with the aim of establishing SmartPAN® as a trusted bioindicator in operating theatres.

Read More SmartPAN®